{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:38:53Z","timestamp":1784763533177,"version":"3.55.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric patients with acute lymphoblastic leukemia and lymphoma (ALL\/LL) and obesity are at increased risk for venous thromboembolism (VTE). The PREVAPIX-ALL trial was an open-label, randomized, controlled trial assessing the safety and efficacy of apixaban for VTE prevention in pediatric patients with ALL\/LL. An a priori subgroup analysis of patients with obesity in the PREVAPIX-ALL trial was planned because of increased VTE risk in this group. Patients with obesity, aged \u22652 to &amp;lt;18 years, central venous catheter, and chemotherapy containing asparaginase were randomized to apixaban (prophylactic dose) vs standard of care (SOC; no anticoagulation) during induction chemotherapy. The primary efficacy end point was a composite of nonfatal symptomatic and asymptomatic VTE and VTE-related death. The primary and secondary safety outcomes were major bleeding and a composite of major and clinically relevant nonmajor (CRNM) bleeding, respectively. A total of 82 PREVAPIX-ALL participants presented with obesity, of whom 42 were randomized to apixaban. For the primary efficacy end point, a significant decrease in VTE events was present in the apixaban arm (1\/42 [2.4%]) as compared with the SOC arm (10\/40 [25%]; relative risk [RR], 0.09; 95% confidence interval [CI], 0.01-0.97; P = .007). There was a statistically significant treatment obesity interaction, P = .03. No statistically significant difference was observed for the primary efficacy end point among the nonobese group (RR, 0.85; 95% CI, 0.53-1.37; P = .50). No statistically significant difference in major or CRNM bleeding was observed. Apixaban prophylaxis in patients with obesity and ALL\/LL resulted in a statistically significant VTE risk reduction with no increase bleeding. This trial was registered at www.clinicaltrials.gov as #NCT02369653.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016160","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:57:16Z","timestamp":1749743836000},"page":"4738-4747","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-544X","authenticated-orcid":false,"given":"Vilmarie","family":"Rodriguez","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9939-6292","authenticated-orcid":false,"given":"Sarah H.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-6818","authenticated-orcid":false,"given":"Etan","family":"Orgel","sequence":"additional","affiliation":[{"name":"2Cancer and Blood Disease Institute, Children\u2019s Hospital Los Angeles, Los Angeles, CA"},{"name":"3Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-1819","authenticated-orcid":false,"given":"Corinna L.","family":"Schultz","sequence":"additional","affiliation":[{"name":"4Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Esbenshade","sequence":"additional","affiliation":[{"name":"5Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arteid","family":"Memaj","sequence":"additional","affiliation":[{"name":"6Biostatistics Medical Affairs, Bristol Myers Squibb, Inc, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Dyme","sequence":"additional","affiliation":[{"name":"7Clinical Science Program, Bristol Myers Squibb, Inc, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Favatella","sequence":"additional","affiliation":[{"name":"7Clinical Science Program, Bristol Myers Squibb, Inc, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley G.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"3","key":"2025093010170495300_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2003.10.013","article-title":"Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"issue":"7","key":"2025093010170495300_bib2","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2025093010170495300_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/rth2.12182","article-title":"Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis","volume":"3","author":"Klaassen","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2025093010170495300_bib4","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.thromres.2018.01.019","article-title":"Thrombosis in pediatric patients with leukemia","volume":"164","author":"Levy-Mendelovich","year":"2018","journal-title":"Thromb Res"},{"issue":"1","key":"2025093010170495300_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2009.01.003","article-title":"Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment","volume":"22","author":"Nowak-G\u00f6ttl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2025093010170495300_bib6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2025093010170495300_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.13236","article-title":"Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study","volume":"14","author":"Tuckuviene","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025093010170495300_bib8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ajh.26193","article-title":"Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C","volume":"96","author":"Pelland-Marcotte","year":"2021","journal-title":"Am J Hematol"},{"issue":"4-5","key":"2025093010170495300_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.thromres.2003.10.007","article-title":"Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"issue":"6","key":"2025093010170495300_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.thromres.2003.10.008","article-title":"Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"issue":"10","key":"2025093010170495300_bib11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00277-018-3371-0","article-title":"The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study","volume":"97","author":"Forbrigger","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"2025093010170495300_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2025093010170495300_bib13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and sesign","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"2025093010170495300_bib14","first-page":"e12787","article-title":"PREVAPIX-ALL: phase 3 study of the safety and efficacy of apixaban for thromboprophylaxis versus standard of care in newly diagnosed pediatric acute lymphoblastic leukemia or lymphoma (ALL\/LL)","volume":"6","author":"O'Brien","year":"2022","journal-title":"Res Prac Thromb Haemost"},{"issue":"1","key":"2025093010170495300_bib15","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O'Brien","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025093010170495300_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1542\/hpeds.2015-0039","article-title":"Association of obesity and pediatric venous thromboembolism","volume":"6","author":"Halvorson","year":"2016","journal-title":"Hosp Pediatr"},{"issue":"2","key":"2025093010170495300_bib17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.atherosclerosis.2010.06.028","article-title":"Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels","volume":"212","author":"Fritsch","year":"2010","journal-title":"Atherosclerosis"},{"issue":"1","key":"2025093010170495300_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0038-1651179","article-title":"Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study","volume":"69","author":"Leone","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"2025093010170495300_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-3848(90)90193-G","article-title":"Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation","volume":"57","author":"Rodeghiero","year":"1990","journal-title":"Thromb Res"},{"issue":"2","key":"2025093010170495300_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1160\/TH14-04-0372","article-title":"Haemostatic alterations induced by treatment with asparaginases and clinical consequences","volume":"113","author":"De Stefano","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"2025093010170495300_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajh.21665","article-title":"Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia","volume":"85","author":"Giordano","year":"2010","journal-title":"Am J Hematol"},{"key":"2025093010170495300_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2018.02.150","article-title":"Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia","volume":"165","author":"Prasca","year":"2018","journal-title":"Thromb Res"},{"key":"2025093010170495300_bib23","unstructured":"U.S. Centers for Disease Control and Prevention\n          . Overweight & obesity. Accessed 1 June 2023. https:\/\/www.cdc.gov\/obesity\/index.html."},{"issue":"9","key":"2025093010170495300_bib24","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025093010170495300_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00001721-200107000-00005","article-title":"Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia","volume":"12","author":"Elhasid","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2-3","key":"2025093010170495300_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0049-3848(03)00099-9","article-title":"An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial","volume":"109","author":"Massicotte","year":"2003","journal-title":"Thromb Res"},{"issue":"2","key":"2025093010170495300_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.11042","article-title":"A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study","volume":"97","author":"Mitchell","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"2025093010170495300_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/08035250600729092","article-title":"Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study","volume":"95","author":"Ruud","year":"2006","journal-title":"Acta Paediatr"},{"issue":"2","key":"2025093010170495300_bib29","first-page":"235","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell","year":"2003","journal-title":"Thromb Haemost"},{"issue":"4","key":"2025093010170495300_bib30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2025093010170495300_bib31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/bjh.17936","article-title":"Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia","volume":"196","author":"Egnell","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2025093010170495300_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/ejh.13517","article-title":"Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols","volume":"105","author":"Egnell","year":"2020","journal-title":"Eur J Haematol"},{"issue":"17","key":"2025093010170495300_bib33","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025093010170495300_bib34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2025093010170495300_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3945\/ajcn.115.124586","article-title":"Association of body mass index and survival in pediatric leukemia: a meta-analysis","volume":"103","author":"Orgel","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"2025093010170495300_bib36","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1097\/MPH.0000000000001127","article-title":"Symptomatic cerebral sinovenous thrombosis associated with L-asparaginase in children with acute lymphoblastic leukemia: a single institution experience over 17 years","volume":"40","author":"Malhotra","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2025093010170495300_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.14238","article-title":"Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence","volume":"175","author":"Dietrich","year":"2016","journal-title":"Br J Haematol"},{"issue":"18","key":"2025093010170495300_bib38","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"2025093010170495300_bib39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pbc.24840","article-title":"Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study","volume":"61","author":"Kumar","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025093010170495300_bib40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1538-7836.2008.02901.x","article-title":"Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia","volume":"6","author":"Kuhle","year":"2008","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4738\/2413516\/blooda_adv-2025-016160-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4738\/2413516\/blooda_adv-2025-016160-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:17:33Z","timestamp":1759241853000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4738\/537763\/Safety-and-efficacy-of-apixaban-thrombosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":40,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016160","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,23]]}}}